SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access

Screening Platform of EORTC for Clinical Trials Access in Brain Tumors

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02307604

Acronym

SPECTAbrain

Enrollment

Registered

2014-12-04

Start date

2016-05-31

Completion date

2019-01-31

Last updated

2019-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Neoplasms

Keywords

Brain tumor, Biomarkers, Screening

Brief summary

The SPECTAbrain protocol describes a structure for screening patients with brain tumors to efficiently allocate eligible patients in relevant therapeutic biomarker-driven clinical trials. Efficiency is promoted through the creation of a clinical database of brain tumor patients and the respective human biological material biobank for molecular characterization. The main objectives are to: * Allocate patients to clinical trials according to the clinical characteristics and molecular profile of their tumor; * Identify or validate new molecularly defined subgroups of tumors; * Investigate the prevalence of novel biomarkers to plan future clinical trials; * Enable exploratory/future research; * Facilitate establishment of quality-assured and validated tests for Central Nervous System (CNS) tumor biomarkers;

Interventions

GENETICTumour markers testing

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Pathologically confirmed newly diagnosed primary CNS tumors, with a focus on diffuse gliomas of grades II, III and IV, meningiomas from patients who are candidates for pharmacotherapy, and rare CNS tumors; * Availability of adequate Human Biological Material (HBM): FFPE tissue sample from the primary and/or recurrent tumor and/or metastasis, obtained at the time of surgery or biopsy; minimal amount requested is detailed in the HBM guidelines. Inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional; * At least three months life expectancy; * Written informed consent according to ICH/GCP and national/local regulations; * Absence of

Exclusion criteria

, such as active hepatitis B/C or HIV, second malignancies, severe organ dysfunction, or other comorbidities that will prevent inclusion into clinical trials.

Design outcomes

Primary

Measure	Time frame
Number of patients with brain malignancy	5 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026